在败血症休克中使用白蛋白替代疗法:一项随机临床试验
Yasser Sakr1,2, Axel Nierhaus3, Ulrike Schumacher4
1Department of Anesthesiology and Intensive Care Therapy, Jena University Hospital, Jena, Germany.
JAMA network open
|February 19, 2026
概括
胺补充剂在性休克患者中没有改善90天的存活率. 这项随机临床试验发现白蛋白是安全的,但由于提前终止,没有确定性,建议进一步研究.
科学领域:
- 关键护理医学 关键护理医学
- 复苏科学复苏科学 复苏科学
- 临床试验 临床试验
背景情况:
- 败血栓冲击管理通常涉及流体复苏.
- 建议服用白蛋白补充剂,以改善败血症休克的结果.
- 有限的随机临床试验数据存在于白蛋白在败血症休克中的有效性.
研究的目的:
- 为了评估白素给药对感染性休克患者的死亡率和其他结局的影响.
- 评估在重症监护病房内补充白蛋白的安全性和有效性.
主要方法:
- 一个多中心的,开放的随机临床试验,涉及患有败血症休克的患者.
- 干预组接受了20%的白蛋白来维持血清水平≥3.0g/dL;对照组接受了标准的晶体液.
- 主要终点是90天死亡率;次要终点包括其他时间点的死亡率和器官功能障碍.
主要成果:
- 专组 (43.3%) 和对照组 (45.9%) 的90天死亡率相似.
- 在二次终点,包括器官功能障碍和28天和60天的死亡率,没有发现显著差异.
- 由于入学率低,试验过早结束,限制了最终的结论.
结论:
- 在性休克患者中服用白蛋白被发现是安全的.
- 胺补充剂没有显示出90天生存率的显著改善.
- 由于试验过早结束,结果不确定的;需要进一步的研究来澄清白蛋白在败血症休克中的作用.
相关概念视频
Acute Kidney Injury IV: Diagnostic Studies and Prevention
362
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
362
Acute Kidney Injury V: Interprofessional Care
374
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
374
Continuous Renal Replacement Therapy
1.3K
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
1.3K
Acute Kidney Injury VI: Nursing Management
523
Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
523
Acute Kidney Injury III: Clinical Manifestations
1.0K
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.0K
Acute Kidney Injury I: Introduction
851
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
851


